Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Transient Receptor Potential Mucolipin-1 Channels in Glioblastoma: Role in Patient's Survival.

Morelli MB, Amantini C, Tomassoni D, Nabissi M, Arcella A, Santoni G.

Cancers (Basel). 2019 Apr 12;11(4). pii: E525. doi: 10.3390/cancers11040525.

2.

18F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.

Cicone F, Carideo L, Scaringi C, Arcella A, Giangaspero F, Scopinaro F, Minniti G.

Ann Nucl Med. 2019 Apr;33(4):295-302. doi: 10.1007/s12149-018-01328-3. Epub 2019 Jan 3.

PMID:
30607877
3.

Effects of aloe emodin on U87MG glioblastoma cell growth: In vitro and in vivo study.

Arcella A, Oliva MA, Staffieri S, Sanchez M, Madonna M, Riozzi B, Esposito V, Giangaspero F, Frati L.

Environ Toxicol. 2018 Nov;33(11):1160-1167. doi: 10.1002/tox.22622. Epub 2018 Sep 15.

PMID:
30218594
4.

Expression of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) in Non-Somatotroph Pituitary Tumours and the Effects of PPARα Agonists on MMQ Cells.

Polidoro MA, Rotondi S, Morace R, Rostomyan L, Colapietro A, Arcella A, Ventura L, Angelucci A, Giangaspero F, Esposito V, Beckers A, Jaffrain-Rea ML.

Horm Metab Res. 2018 Aug;50(8):640-647. doi: 10.1055/a-0633-2706. Epub 2018 Jul 18.

5.

Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.

Arcella A, Palchetti S, Digiacomo L, Pozzi D, Capriotti AL, Frati L, Oliva MA, Tsaouli G, Rota R, Screpanti I, Mahmoudi M, Caracciolo G.

ACS Chem Neurosci. 2018 Dec 19;9(12):3166-3174. doi: 10.1021/acschemneuro.8b00339. Epub 2018 Jul 31.

PMID:
30015470
6.

Integrated DNA methylation analysis identifies topographical and tumoral biomarkers in pilocytic astrocytomas.

Antonelli M, Fadda A, Loi E, Moi L, Zavattari C, Sulas P, Gentilini D, Cameli C, Bacchelli E, Badiali M, Arcella A, Morra I, Giangaspero F, Zavattari P.

Oncotarget. 2018 Feb 12;9(17):13807-13821. doi: 10.18632/oncotarget.24480. eCollection 2018 Mar 2.

7.

Loss of constitutive functional γ-aminobutyric acid type A-B receptor crosstalk in layer 5 pyramidal neurons of human epileptic temporal cortex.

Martinello K, Sciaccaluga M, Morace R, Mascia A, Arcella A, Esposito V, Fucile S.

Epilepsia. 2018 Feb;59(2):449-459. doi: 10.1111/epi.13991. Epub 2017 Dec 28.

8.

Role of Immunohistochemistry in the Identification of Supratentorial C11ORF95-RELA Fused Ependymoma in Routine Neuropathology.

Gessi M, Giagnacovo M, Modena P, Elefante G, Gianno F, Buttarelli FR, Arcella A, Donofrio V, Diomedi Camassei F, Nozza P, Morra I, Massimino M, Pollo B, Giangaspero F, Antonelli M.

Am J Surg Pathol. 2019 Jan;43(1):56-63. doi: 10.1097/PAS.0000000000000979.

PMID:
29266023
9.

Concomitant IDH wild-type glioblastoma and IDH1-mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome.

Galuppini F, Opocher E, Tabori U, Mammi I, Edwards M, Campbell B, Kelly J, Viel A, Quaia M, Rivieri F, D'Avella D, Arcella A, Giangaspero F, Fassan M, Gardiman MP.

Neuropathol Appl Neurobiol. 2018 Feb;44(2):233-239. doi: 10.1111/nan.12450. No abstract available.

PMID:
29130549
10.

Expression of large neutral amino acid transporters LAT1 and LAT2 in medulloblastoma.

Cicone F, Minniti G, Oliva MA, Carideo L, Prior JO, Scopinaro F, Giangaspero F, Arcella A.

Brain Tumor Pathol. 2017 Oct;34(4):179-181. doi: 10.1007/s10014-017-0296-6. Epub 2017 Aug 16. No abstract available.

PMID:
28815339
11.

Effects of hispolon on glioblastoma cell growth.

Arcella A, Oliva MA, Sanchez M, Staffieri S, Esposito V, Giangaspero F, Cantore G.

Environ Toxicol. 2017 Sep;32(9):2113-2123. doi: 10.1002/tox.22419. Epub 2017 Jun 15.

PMID:
28618133
12.

Mitochondrial AKAP1 supports mTOR pathway and tumor growth.

Rinaldi L, Sepe M, Delle Donne R, Conte K, Arcella A, Borzacchiello D, Amente S, De Vita F, Porpora M, Garbi C, Oliva MA, Procaccini C, Faicchia D, Matarese G, Zito Marino F, Rocco G, Pignatiello S, Franco R, Insabato L, Majello B, Feliciello A.

Cell Death Dis. 2017 Jun 1;8(6):e2842. doi: 10.1038/cddis.2017.241.

13.

Post-transcriptional regulation of 5'-untranslated regions of human Transient Receptor Potential Vanilloid type-1 (TRPV-1) channels: role in the survival of glioma patients.

Nabissi M, Morelli MB, Arcella A, Cardinali C, Santoni M, Bernardini G, Santoni A, Santoni G, Amantini C.

Oncotarget. 2016 Dec 6;7(49):81541-81554. doi: 10.18632/oncotarget.13132.

14.

SMARCB1/INI1 Involvement in Pediatric Chordoma: A Mutational and Immunohistochemical Analysis.

Antonelli M, Raso A, Mascelli S, Gessi M, Nozza P, Coli A, Gardiman MP, Arcella A, Massimino M, Buttarelli FR, Giangaspero F.

Am J Surg Pathol. 2017 Jan;41(1):56-61.

PMID:
27635948
15.

Overexpression of transient receptor potential mucolipin-2 ion channels in gliomas: role in tumor growth and progression.

Morelli MB, Nabissi M, Amantini C, Tomassoni D, Rossi F, Cardinali C, Santoni M, Arcella A, Oliva MA, Santoni A, Polidori C, Mariani MP, Santoni G.

Oncotarget. 2016 Jul 12;7(28):43654-43668. doi: 10.18632/oncotarget.9661.

16.

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.

De Divitiis C, von Arx C, Grimaldi AM, Cicala D, Tatangelo F, Arcella A, Romano GM, Simeone E, Iaffaioli RV, Ascierto PA, Tafuto S; European Neuroendocrine Tumor Society (ENETS) Center of Excellence-Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy).

J Transl Med. 2016 May 3;14(1):113. doi: 10.1186/s12967-016-0857-1.

17.

Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells.

Rotondi S, Modarelli A, Oliva MA, Rostomyan L, Sanita P, Ventura L, Daly AF, Esposito V, Angelucci A, Arcella A, Giangaspero F, Beckers A, Jaffrain-Rea ML.

Mol Cell Endocrinol. 2016 May 5;426:61-72. doi: 10.1016/j.mce.2016.02.005. Epub 2016 Feb 10.

PMID:
26872613
18.

SDS-PAGE analysis of Aβ oligomers is disserving research into Alzheimer´s disease: appealing for ESI-IM-MS.

Pujol-Pina R, Vilaprinyó-Pascual S, Mazzucato R, Arcella A, Vilaseca M, Orozco M, Carulla N.

Sci Rep. 2015 Oct 9;5:14809. doi: 10.1038/srep14809.

19.

In vitro and in vivo effect of human lactoferrin on glioblastoma growth.

Arcella A, Oliva MA, Staffieri S, Aalberti S, Grillea G, Madonna M, Bartolo M, Pavone L, Giangaspero F, Cantore G, Frati A.

J Neurosurg. 2015 Oct;123(4):1026-35. doi: 10.3171/2014.12.JNS14512. Epub 2015 Jul 17.

PMID:
26186026
20.

Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.

Minniti G, Scaringi C, Lanzetta G, Terrenato I, Esposito V, Arcella A, Pace A, Giangaspero F, Bozzao A, Enrici RM.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):109-15. doi: 10.1016/j.ijrobp.2014.09.013. Epub 2014 Oct 25.

PMID:
25442339
21.

Structure and dynamics of oligonucleotides in the gas phase.

Arcella A, Dreyer J, Ippoliti E, Ivani I, Portella G, Gabelica V, Carloni P, Orozco M.

Angew Chem Int Ed Engl. 2015 Jan 7;54(2):467-71. doi: 10.1002/anie.201406910. Epub 2014 Nov 21.

PMID:
25417598
22.

Structure and properties of DNA in apolar solvents.

Arcella A, Portella G, Collepardo-Guevara R, Chakraborty D, Wales DJ, Orozco M.

J Phys Chem B. 2014 Jul 24;118(29):8540-8. doi: 10.1021/jp503816r. Epub 2014 Jul 14.

23.

IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.

Minniti G, Scaringi C, Arcella A, Lanzetta G, Di Stefano D, Scarpino S, Bozzao A, Pace A, Villani V, Salvati M, Esposito V, Giangaspero F, Enrici RM.

J Neurooncol. 2014 Jun;118(2):377-383. doi: 10.1007/s11060-014-1443-0. Epub 2014 Apr 20.

PMID:
24748470
24.

High-throughput microRNA profiling of pediatric high-grade gliomas.

Miele E, Buttarelli FR, Arcella A, Begalli F, Garg N, Silvano M, Po A, Baldi C, Carissimo G, Antonelli M, Spinelli GP, Capalbo C, Donofrio V, Morra I, Nozza P, Gulino A, Giangaspero F, Ferretti E.

Neuro Oncol. 2014 Jan;16(2):228-40. doi: 10.1093/neuonc/not215. Epub 2013 Dec 4.

25.

Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers.

Minniti G, Arcella A, Scaringi C, Lanzetta G, Di Stefano D, Scarpino S, Pace A, Giangaspero F, Osti MF, Enrici RM.

J Neurooncol. 2014 Jan;116(2):275-82. doi: 10.1007/s11060-013-1288-y. Epub 2013 Oct 26.

PMID:
24162810
26.

Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth.

Lignitto L, Arcella A, Sepe M, Rinaldi L, Delle Donne R, Gallo A, Stefan E, Bachmann VA, Oliva MA, Tiziana Storlazzi C, L'Abbate A, Brunetti A, Gargiulo S, Gramanzini M, Insabato L, Garbi C, Gottesman ME, Feliciello A.

Nat Commun. 2013;4:1822. doi: 10.1038/ncomms2791.

27.

Rapamycin inhibits the growth of glioblastoma.

Arcella A, Biagioni F, Antonietta Oliva M, Bucci D, Frati A, Esposito V, Cantore G, Giangaspero F, Fornai F.

Brain Res. 2013 Feb 7;1495:37-51. doi: 10.1016/j.brainres.2012.11.044. Epub 2012 Dec 19.

PMID:
23261661
28.

Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.

Ciceroni C, Bonelli M, Mastrantoni E, Niccolini C, Laurenza M, Larocca LM, Pallini R, Traficante A, Spinsanti P, Ricci-Vitiani L, Arcella A, De Maria R, Nicoletti F, Battaglia G, Melchiorri D.

Cell Death Differ. 2013 Mar;20(3):396-407. doi: 10.1038/cdd.2012.150. Epub 2012 Nov 23.

29.

Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.

Salvati M, Pichierri A, Piccirilli M, Floriana Brunetto GM, D'Elia A, Artizzu S, Santoro F, Arcella A, Giangaspero F, Frati A, Simione L, Santoro A.

J Neurosurg. 2012 Aug;117(2):204-11. doi: 10.3171/2012.4.JNS101702. Epub 2012 Jun 1.

PMID:
22655594
30.

KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults.

Badiali M, Gleize V, Paris S, Moi L, Elhouadani S, Arcella A, Morace R, Antonelli M, Buttarelli FR, Figarella-Branger D, Kim YH, Ohgaki H, Mokhtari K, Sanson M, Giangaspero F.

Brain Pathol. 2012 Nov;22(6):841-7. doi: 10.1111/j.1750-3639.2012.00603.x. Epub 2012 Jun 18.

PMID:
22591444
31.

Structure of triplex DNA in the gas phase.

Arcella A, Portella G, Ruiz ML, Eritja R, Vilaseca M, Gabelica V, Orozco M.

J Am Chem Soc. 2012 Apr 18;134(15):6596-606. doi: 10.1021/ja209786t. Epub 2012 Apr 6.

PMID:
22420643
32.

Single brain metastases from cervical carcinoma: report of two cases and critical review of the literature.

Marongiu A, Salvati M, D'Elia A, Arcella A, Giangaspero F, Esposito V.

Neurol Sci. 2012 Aug;33(4):937-40. doi: 10.1007/s10072-011-0861-4. Epub 2011 Nov 24. Review.

PMID:
22113230
33.

Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.

Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A, De Sanctis V, Giangaspero F, Enrici RM.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):93-9. doi: 10.1016/j.ijrobp.2011.06.1992. Epub 2011 Nov 11.

PMID:
22079725
34.

Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL40 and prognostic significance.

Antonelli M, Massimino M, Morra I, Garrè ML, Gardiman MP, Buttarelli FR, Arcella A, Giangaspero F.

Neuropathology. 2012 Apr;32(2):133-8. doi: 10.1111/j.1440-1789.2011.01252.x. Epub 2011 Oct 6.

PMID:
21978279
35.

Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression.

Calogero A, Porcellini A, Lombari V, Fabbiano C, Arcella A, Miscusi M, Ponti D, Ragona G.

Cancer Cell Int. 2011 Mar 2;11:5. doi: 10.1186/1475-2867-11-5.

36.

Claudin-6 is of limited sensitivity and specificity for the diagnosis of atypical teratoid/rhabdoid tumors.

Antonelli M, Hasselblatt M, Haberler C, Di Giannatale A, Garrè ML, Donofrio V, Lauriola L, Ridola V, Arcella A, Frühwald M, Giangaspero F.

Brain Pathol. 2011 Sep;21(5):558-63. doi: 10.1111/j.1750-3639.2011.00478.x. Epub 2011 Mar 16.

PMID:
21261775
37.

Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.

Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, Lanzetta G, Scarpino S, Arcella A, Enrici RM.

Radiother Oncol. 2010 Dec;97(3):377-81. doi: 10.1016/j.radonc.2010.08.020. Epub 2010 Sep 18.

PMID:
20855119
38.

Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.

Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrici R, Giangaspero F.

J Neurooncol. 2011 Apr;102(2):311-6. doi: 10.1007/s11060-010-0324-4. Epub 2010 Aug 5.

PMID:
20686820
39.

Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.

Buttarelli FR, Massimino M, Antonelli M, Lauriola L, Nozza P, Donofrio V, Arcella A, Oliva MA, Di Rocco C, Giangaspero F.

Childs Nerv Syst. 2010 Aug;26(8):1051-6. doi: 10.1007/s00381-010-1191-1. Epub 2010 Jun 16.

PMID:
20552207
40.

Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.

Iyer AM, Zurolo E, Boer K, Baayen JC, Giangaspero F, Arcella A, Di Gennaro GC, Esposito V, Spliet WG, van Rijen PC, Troost D, Gorter JA, Aronica E.

Neuroscience. 2010 May 19;167(3):929-45. doi: 10.1016/j.neuroscience.2010.02.047. Epub 2010 Feb 26.

PMID:
20219643
41.

Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.

Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, Giangaspero F.

J Neurooncol. 2010 Sep;99(2):209-15. doi: 10.1007/s11060-010-0129-5. Epub 2010 Feb 21.

PMID:
20174854
42.

TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner.

Nabissi M, Morelli MB, Amantini C, Farfariello V, Ricci-Vitiani L, Caprodossi S, Arcella A, Santoni M, Giangaspero F, De Maria R, Santoni G.

Carcinogenesis. 2010 May;31(5):794-803. doi: 10.1093/carcin/bgq019. Epub 2010 Jan 21.

PMID:
20093382
43.

Blockage of A2A and A3 adenosine receptors decreases the desensitization of human GABA(A) receptors microtransplanted to Xenopus oocytes.

Roseti C, Palma E, Martinello K, Fucile S, Morace R, Esposito V, Cantore G, Arcella A, Giangaspero F, Aronica E, Mascia A, Di Gennaro G, Quarato PP, Manfredi M, Cristalli G, Lambertucci C, Marucci G, Volpini R, Limatola C, Eusebi F.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15927-31. doi: 10.1073/pnas.0907324106. Epub 2009 Aug 31.

44.

Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status.

Barresi V, Buttarelli FR, Vitarelli EE, Arcella A, Antonelli M, Giangaspero F.

Hum Pathol. 2009 Dec;40(12):1738-46. doi: 10.1016/j.humpath.2009.04.026. Epub 2009 Aug 27.

PMID:
19716156
45.

Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications.

Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen JF, D'Innocenzo E, Barlier A, Giangaspero F, Esposito V, Ventura L, Arcella A, Theodoropoulou M, Naves LA, Fajardo C, Zacharieva S, Rohmer V, Brue T, Gulino A, Cantore G, Alesse E, Beckers A.

Endocr Relat Cancer. 2009 Sep;16(3):1029-43. doi: 10.1677/ERC-09-0094. Epub 2009 Jun 25.

46.

Pathological and molecular heterogeneity of medulloblastoma.

Gulino A, Arcella A, Giangaspero F.

Curr Opin Oncol. 2008 Nov;20(6):668-75. doi: 10.1097/CCO.0b013e32831369f4. Review.

PMID:
18841049
47.

Adenosine receptor antagonists alter the stability of human epileptic GABAA receptors.

Roseti C, Martinello K, Fucile S, Piccari V, Mascia A, Di Gennaro G, Quarato PP, Manfredi M, Esposito V, Cantore G, Arcella A, Simonato M, Fredholm BB, Limatola C, Miledi R, Eusebi F.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15118-23. doi: 10.1073/pnas.0807277105. Epub 2008 Sep 22.

48.

Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells.

Ciceroni C, Arcella A, Mosillo P, Battaglia G, Mastrantoni E, Oliva MA, Carpinelli G, Santoro F, Sale P, Ricci-Vitiani L, De Maria R, Pallini R, Giangaspero F, Nicoletti F, Melchiorri D.

Neuropharmacology. 2008 Sep;55(4):568-76. doi: 10.1016/j.neuropharm.2008.06.064. Epub 2008 Jul 8.

PMID:
18621067
49.

Metabotropic glutamate receptors: beyond the regulation of synaptic transmission.

Nicoletti F, Battaglia G, Storto M, Ngomba RT, Iacovelli L, Arcella A, Gradini R, Sale P, Rampello L, De Vita T, Di Marco R, Melchiorri D, Bruno V.

Psychoneuroendocrinology. 2007 Aug;32 Suppl 1:S40-5. Epub 2007 Jul 24. Review.

PMID:
17651904
50.

Intracellular distribution of beta-catenin in human medulloblastoma cell lines with different degree of neuronal differentiation.

Salaroli R, Russo A, Ceccarelli C, Mina GD, Arcella A, Martinelli GN, Giangaspero F, Capranico G, Cenacchi G.

Ultrastruct Pathol. 2007 Jan-Feb;31(1):33-44.

PMID:
17455096

Supplemental Content

Loading ...
Support Center